Will hackers use your own AI against you?
Businesses have spent years asking what AI can do for their employees. Fewer have asked what it would do for an intruder inside an employee’s account.
Lawsuit costs Bentley
A European lawsuit and settlement has cost Bentley Pharmaceuticals more than $10 million, the company announced Thursday.
Almost $9 million of the loss was charged in the last quarter, contributing to a net loss of $7.2 million, or 33 cents a share, the Exeter-based generic drug company said.
The legal costs spoiled a record quarterly sales report of $25.2 million, and the news that the federal Food and Drug Administration approved the company’s potentially lucrative insulin nasal spray has been approved for Phase 2 testing.
Ethypharm, based in Spain and France, had alleged that Bentley – which manufactures and sells most of its products in Europe – had illegally appropriated Ethypharm’s pellet technology. As a result Bentley agreed to a settlement of $4 million up front, and another four payments of $1 million annually. In addition, the company incurred up to $1.4 million in defense costs for the third quarter of 2006 alone.
In the first three quarters, the company, the litigation and legal expenses added up to $10.27 million, of which $8.9 million were charged to the third quarter.
The company’s third-quarter sales of $25.2 million were 7 percent higher than the sales during the same period last year, but because of increased expenses, the company’s net sales were $9.7 million below the third quarter of 2005, when Bentley made some $2.5 million. This resulted in a 44-cent-a-share downturn. – BOB SANDERS
